Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Study of Disitamab Vedotin Alone or with Pembrolizumab in Urothelial Cancer That Expresses HER2
- Conditions
- Urothelial carcinoma
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 14
- Registration Number
- 2022-500030-28-01
- Locations
- 🇺🇸
Banner Gateway Medical Center, Gilbert, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Kaiser Permanente Anaheim Kraemer Medical Offices, Anaheim, California, United States
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 502
- Registration Number
- NCT04697628
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
🇺🇸Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
A Study of SGN-STNV in Advanced Solid Tumors
- Conditions
- Ovarian NeoplasmsPseudomyxoma PeritoneiUterine Cervical NeoplasmsGastroesophageal Junction CarcinomaStomach NeoplasmsAppendiceal AdenocarcinomaEsophageal NeoplasmsExocrine Pancreatic AdenocarcinomaCarcinoma, Non-Small Cell LungHER2 Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT04665921
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California, United States
🇺🇸Shands Cancer Center / University of Florida, Gainesville, Florida, United States
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
- Conditions
- Non-small Cell Lung CancerMelanomaSquamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 140
- Registration Number
- NCT04609566
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇺🇸California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas, California, United States
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Conditions
- Biliary Tract NeoplasmsUterine NeoplasmsUrologic NeoplasmsCarcinoma, Non-Small-Cell LungHER2 Mutations Breast NeoplasmsUterine Cervical Neoplasms
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 217
- Registration Number
- NCT04579380
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL, Goodyear, Arizona, United States
🇺🇸HonorHealth, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT04569032
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Stanford Cancer Center / Blood and Marrow Transplant Program, Stanford, California, United States
🇺🇸Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT04539938
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- Other: tucatinib placeboOther: trastuzumab placebo
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04499924
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Conditions
- GEJ AdenocarcinomaCholangiocarcinomaGallbladder CarcinomaColorectal CarcinomaEsophageal AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT04430738
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸University of Colorado Denver CTO(CTRC), Aurora, Colorado, United States
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 241
- Registration Number
- NCT04404283
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - NAHOA, Goodyear, Arizona, United States